This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Mindray Medical International Limited (MR), a China-based medical devices firm, is our top investment idea for the coming year," says Alan Newman.

In his CrossCurrents newsletter, he notes, "The company is headquartered in Shenzhen, China, and is one of many Chinese companies now specializing in the development, manufacture and marketing of medical devices worldwide.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

J. Royden Ward is the editor of The Cabot Benjamin Graham Value Letter, a newsletter that -- as its name suggests -- focuses on stocks that meet the criteria of legendary value investor Ben Graham.

For his top pick for 2010, he the advisor looks to Amedisys (AMED), a provider of home health care and hospice services.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My top stock pick for 2010 is MannKind Corp. (MNKD), which is developing a a novel formulation of inhalable insulin called Afresa," notes Nate Pile.

In his Nate's Notes newsletter, he explains, "I would emphasize that while the stock must be considered speculative until the FDA delivers a ruling in mid-January of next year, I believe the clinical data that has been submitted by the company is likely to warrant approval."

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"Medical equipment giant Becton, Dickinson and Co. (BDX) is our top investment pick for the coming year," says Jonas Elmerraji. Here's his review from the advisor's Rhino Stock Report.

"If anything's certain for 2010, it'll be that nothing's certain as far as stocks are concerned. With a substantial rally that's pushed the valuations of major indexes like the S&P 500 and Dow more than 60% higher since mid-March lows, it's inevitable for investor anxiety to spill over into the New Year.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

"My number one stock pick to start 2010 is Medifast Inc. (MED), a weight and disease management company," says Mike Turner.

The editor of Mastering the Markets explains, "The stock has skyrocketed from the $5 area to over $30 in just the last nine months." Despite the gains, the advisor remains bullish on the stock's prospects.

This post is part of a special report, Top Picks for 2010, the 27th annual survey in which TheStockAdvisors.com asks the nation's leading advisors for their single favorite stock for the new year. See all 80 stocks listed here.

In the Upside newsletter, quantitative analyst Richard Moroney uses a proprietary system called Quadrix, a screening model that assesses stocks based on nearly 100 fundamental and technical variables.

Virtual Radiologic (VRAD) earns the Quadrix systems "best buy rating" and is the advisor's favorite investment pick for the coming year.

"The health care business is immune to an ill economy, as people still need vaccinations, sutures and blood screens regardless of business cycles," notes value investor Nathan Slaughter.

In his Half-Priced Stocks, he suggests, "When it comes to medical waste disposal, demand is constant and barriers to entry are high." To play this specialty sector, he looks to Stericycle (SRCL).

"Stericycle is the dominant player in this field. The firm safely empties all those bins, and also removes discarded waste from research facilities, laboratories, hospitals, surgical centers, pharmacies, veterinary clinics and even dentists' offices.

It's now or never, as far as realizing an outsized gain with medical device supplier Covidien Plc (COV), which is why I'm reiterating my buy rating for the company's share's, first recommended on June 4, 2009 at a price of $35.65. If you bought COV in June, you're up about 35%.

Further, the investment calculation with Covidien isn't rocket science: an aging U.S. population and the likelihood that U.S. public policy will universalize health care means that roughly 3-5 million more citizens per year for the next 8-10 years will receive regular health care services. And that means one thing: it's a good time to be a medical supplier (or a nurse, or radiologist, or surgeon, etc.).

"Walgreen (NYSE: WAG) reported fourth quarter profits that topped Wall Street's expectations," says Geoffrey Seiler.

In his BullMarket,com advisory, he forecasts, "We expect to see continued operational improvements in the months ahead." Here, the advisor reiterates his buy rating and boosts his price target for the stock.

The advisor observes,, "The company reported a net profit of $436 million, or 44 cents per share, for the quarter ended August 31st, a -1.5% decrease the same quarter a year ago. Results topped the Wall Street consensus by 5 cents share and edged the full-year EPS estimate by 3 cents.

"The health care picks in our growth portfolio should prosper whatever the outcome of the raging health care debate," suggests growth stock specialist Stephen Leeb.

In The Complete Investor, he explains, "That's because they're leveraged to demographic realities, and in particular to the tide of aging baby boomers," Here, he reviews on portfolio holding -- Teva Pharmaceuticals (NASDAQ: TEVA).

Leeb says, "Israel-based Teva Pharmaceutical is the world's largest manufacturer of generic drugs. Capitalized at $49 billion, Teva pulled in some $11 billion in revenues in 2008, with generic drugs contributing more than two-thirds of those sales.

"Being contrarians, we are always looking for laggard stocks with the potential to rebound," says turnaround expert George Putnam.

In his The Turnaround Letter, the advisor reviews four medical and pharmaceutical stocks that have been among the worst performers in the S&P 100 since the market bottom. Despite their poor performance, he thinks they may be due for a rebound.

"We think that investors who got left behind by the first leg of the market rally are struggling to catch up.

Medtronic (NYSE: MDT), a manufacturer of a whole host of medical devices involved with the management of diabetes and cardiovascular disease, released its Q1 data on Tuesday. Revenues increased 6%, and adjusted earnings per share came in at 79 cents (some of the adjustments were related to restructuring and litigation issues).

The company was able to grow the adjusted-per-share bottom line by 10%. In addition, according to Reuters, Medtronic beat estimates by a penny. Shareholders should keep in mind, however, that the quarter benefited from an extra week.

"Healthcare-related stocks have been trading up and down based on the latest rumor of how the Obama medical plan might be implemented," observes analyst Glenn Rogers.

The contributing editor to Gordon Pape's Internet Wealth Builder asks, "How can we benefit from Obama-Care?" Here, the advisor looks at Walgreen (NYSE: WAG), the largest drugstore chain in the U.S."

"A recent article in Barron's suggested that Walgreens, Caremark CVS, and Target could benefit from whatever new healthcare system emerges from Congress. (Note, Caremark CVS was covered in a previous post today.)

"Regardless of how you analyze the company, CVS Caremark (NYSE: CVS) stands out," says Chuck Carlson.

In The DRIP Investor, he explains, "Our Quadrix stock-rating system ranks more than 4,000 stocks based on more than 100 different variables. CVS scores better than 90% of the stocks in the Quadrix universe."

"CVS's Sector score -- that is, a score devised by evaluating the metrics that have the most influence over performance in that particular sector -- is also impressive at 95 out of a possible 100.

"Johnson & Johnson (NYSE: JNJ) has vast holdings, but its strategy is simple: Support a deep pipeline of new drugs and medical devices with an aggressive acquisition strategy and cost controls," notes blue chip investor Richard Moroney.

In his Dow Theory Forecasts, he adds, "And despite the recession, J&J has kept its financial footing, remaining one of the few companies with the top credit rating of AAA." Here's his long term outlook.

"This year the U.S. pharmaceutical market is expected to contract for the first time in 50 years as fewer people visit doctors or start new therapies for chronic conditions.

"Beyond 2009, an economic recovery should reinvigorate J&J, though it is too early to determine whether health-care reform will help or harm the company.